Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Basic Clin Pharmacol Toxicol. 2012 Dec;111(6):417-25. doi: 10.1111/j.1742-7843.2012.00931.x. Epub 2012 Sep 25.
Acetaminophen (APAP) overdose is currently the most frequent cause of drug-induced liver failure in the United States. Recently, it was shown that lysosomal iron translocates to mitochondria where it contributes to the collapse of the mitochondrial membrane potential. Therefore, the purpose of this study was to investigate whether cathepsin B, a lysosomal protease, is involved in APAP-induced hepatotoxicity. Cathepsin B activity was measured in subcellular liver fractions of C57Bl/6 mice 3 hr after 300 mg/kg APAP treatment. There was a significant increase in cytoplasmic cathepsin activity, concurrent with a decrease in microsomal activity, indicative of lysosomal cathepsin B release. To investigate the effect of cathepsin B on hepatotoxicity, the cathepsin inhibitor AC-LVK-CHO was given 1 hr prior to 300 mg/kg APAP treatment along with vehicle control. There was no difference between groups in serum alanine aminotransferase (ALT) values, or by histological evaluation of necrosis, although cathepsin B activity was inhibited by 70-80% compared with controls. These findings were confirmed with a different inhibitor (z-FA-fmk) in vivo and in vitro. Hepatocytes were exposed to 5 mM acetaminophen. Lysotracker staining confirmed lysosomal instability and cathepsin B release, but there was no reduction in cell death after treatment with cathepsin B inhibitors. Finally, cathepsin B release was measured in clinical samples from patients with APAP-induced liver injury. Low levels of cathepsin B were released into plasma from overdose patients. APAP overdose causes lysosomal instability and release of cathepsin B into the cytosol but does not contribute to liver injury under these conditions.
对乙酰氨基酚(APAP)过量是目前美国药物性肝衰竭最常见的原因。最近的研究表明,溶酶体铁转运到线粒体,导致线粒体膜电位崩溃。因此,本研究旨在探讨溶酶体蛋白酶组织蛋白酶 B 是否参与 APAP 诱导的肝毒性。在 C57Bl/6 小鼠经 300mg/kg APAP 处理 3 小时后,测定亚细胞肝脏部分的组织蛋白酶 B 活性。细胞质组织蛋白酶活性显著增加,同时微粒体活性降低,表明溶酶体组织蛋白酶 B 释放。为了研究组织蛋白酶 B 对肝毒性的影响,在给予 300mg/kg APAP 前 1 小时给予组织蛋白酶抑制剂 AC-LVK-CHO ,并给予载体对照。与对照组相比,各组血清丙氨酸氨基转移酶(ALT)值或坏死的组织学评价均无差异,尽管组织蛋白酶 B 活性抑制了 70-80%。这些发现通过体内和体外的不同抑制剂(z-FA-fmk)得到了证实。肝细胞暴露于 5mM 对乙酰氨基酚。溶酶体追踪染色证实了溶酶体不稳定和组织蛋白酶 B 释放,但在用组织蛋白酶 B 抑制剂处理后,细胞死亡没有减少。最后,测定了 APAP 诱导肝损伤患者的临床样本中的组织蛋白酶 B 释放。过量患者的血浆中释放出低水平的组织蛋白酶 B。APAP 过量导致溶酶体不稳定和组织蛋白酶 B 释放到细胞质中,但在这些条件下不会导致肝损伤。